Boswellia for osteoarthritis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00133973" target="_blank" >RIV/00216224:14110/22:00133973 - isvavai.cz</a>
Result on the web
<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014969/full" target="_blank" >https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014969/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/14651858.CD014969" target="_blank" >10.1002/14651858.CD014969</a>
Alternative languages
Result language
angličtina
Original language name
Boswellia for osteoarthritis
Original language description
Osteoarthritis (OA) is a common, chronic disorder of the joints that imparts a substantial and ever‐increasing health burden, especially in the elderly population (Cross 2014; Glyn‐Jones 2015). OA affects 7% of the global population and is responsible for 2% of total global years lived with disability (GBD 2020). OA prevalence is higher in women, and increases with advancing age and increasing body mass index (BMI (Palazzo 2016)). Due to the increasing prevalence of obesity and an ageing global population, the prevalence of OA has been steadily increasing over the past few decades (GBD 2020). OA is a leading cause of chronic pain and long‐term disability in adults; its major symptoms include joint pain, stiffness, and joint functional loss (Martel‐Pelletier 2016). OA most commonly affects the joints in the knees, hips, hand, foot, ankle, back, and neck (Kapoor 2015). The pathogenesis of OA is complex, and involves a dynamic process mediated by mechanical, inflammatory, and metabolic factors (Katz 2021; Mobasheri 2016). The current treatment guidelines for OA list few management options, which include non‐pharmacological and pharmacological options. Non‐pharmacological treatments are the core treatment option for the management of OA, and include weight loss, self‐management and education programmes, and physical exercise. Pharmacological treatments include oral nonsteroidal anti‐inflammatory drugs (NSAIDs) in those without contraindications, topical NSAIDs, and glucocorticoid injections (Bannuru 2019; Fransen 2015; Katz 2021; Messier 2013; Rini 2015). NSAIDs are often the first‐line pharmacologic treatment for OA; however, they are often contraindicated in people with OA, who often have comorbidities (Honvo 2019; Mason 2004; Rannou 2016).
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30304 - Public and environmental health
Result continuities
Project
<a href="/en/project/EF18_053%2F0016952" target="_blank" >EF18_053/0016952: Postdoc2MUNI</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cochrane Database of Systematic Reviews
ISSN
1469-493X
e-ISSN
1361-6137
Volume of the periodical
10
Issue of the periodical within the volume
October 2022
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
1-14
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85140243062